ストックスクリーナーアプリを入手
10.32
4.29%
-0.4631
アフターアワーズ：
10.32
前日終値:
$10.78
開ける：
$10.3
24時間の取引高:
2,024
Relative Volume:
0.03
時価総額：
$24.79M
収益：
-
当期純損益:
$-3.34M
株価収益率:
-3.8229
EPS:
-2.6995
ネットキャッシュフロー:
$-10.54M
1週間 パフォーマンス:
-1.81%
1か月 パフォーマンス:
-28.13%
6か月 パフォーマンス:
-18.16%
1年 パフォーマンス:
+57.80%
1日の値動き範囲:
$10.17
$10.47
1週間の範囲:
$10.08
$11.00
52週間の値動き範囲:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
10.32 | 25.88M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polyrizon Ltd (PLRZ) 最新ニュース
Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss - TipRanks
A 9.99% ownership limit restricts exercise of Polyrizon (PLRZ) share purchase rights. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
Polyrizon (PLRZ) Slides 2.20% to $10.66 as Shares Drift Toward $10.13 SupportIndex Put Call - siam.in
Polyrizon enrolls first patient in U.S. allergy blocker trial By Investing.com - Investing.com South Africa
Polyrizon enrolls first patient in U.S. allergy blocker trial - Investing.com
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker - The Manila Times
A drug-free nasal spray enters human testing for allergies. Polyrizon enrolled the first patient. - Stock Titan
Single investor clears new Polyrizon (PLRZ) shares to resell - Stock Titan
Biotech Polyrizon (PLRZ) completes new warrant funding - Stock Titan
Polyrizon (NASDAQ: PLRZ) Announces Offering of 232,500 Shares at $12.00 Plus 30,000 Pre-Funded Warrants - kalkinemedia.com
Polyrizon announces closing of registered direct offering - Medical Buyer
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement - TipRanks
Single investor funds new Polyrizon (PLRZ) cash raise - Stock Titan
Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor - blockonomi.com
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement - Quiver Quantitative
One investor puts about $4 million into Polyrizon - Stock Titan
$4M funding deal gives Polyrizon (PLRZ) investor long-term warrant rights - stocktitan.net
Polyrizon raises $4 million in registered direct offering By Investing.com - Investing.com Nigeria
Polyrizon raises $4 million in registered direct offering - Investing.com
One investor agreed to buy Polyrizon shares and warrants; proceeds are expected at about $4 million. - Stock Titan
Polyrizon (PLRZ) Holds Near $12.56: Small-Cap Pharma Stock Faces Key Technical TestSymmetrical Triangle - dars.gov.et
Polyrizon completes contracting for allergy blocker trial sites By Investing.com - Investing.com South Africa
Polyrizon Tumbles on Clinical Studies - baystreet.ca
Polyrizon completes contracting for allergy blocker trial sites - Investing.com
Polyrizon Completes U.S. Clinical Site Contracting for NASARIX Allergy Blocker Study - Quiver Quantitative
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - FinancialContent
Polyrizon (PLRZ) Trading: Ends Down by 1.40% at $10.53 in Latest Trading; the Current Price Sits Inside the Supplied Technical Range in the Latest SessionAnalyst Downgrade Signals - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon (PLRZ) Latest: Closes 6.26% Lower at $10.49 in the Current Update; Range Check: Support at $9.97 and Resistance at $11.01 Frame the Range in Latest TradingWyckoff Accumulation - vinanet.vn
Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study - TipRanks
Polyrizon (PLRZ) lines up sites for 120-patient allergy study - Stock Titan
Polyrizon completes contracting with all five clinical sites By Investing.com - Investing.com South Africa
Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study - Quiver Quantitative
Polyrizon's planned allergy study will compare its spray with saline in up to 120 patients - Stock Titan
Polyrizon (PLRZ) Close and Levels: Records a 5.65% Decrease to $10.36 for the Current Session; Nearby Levels: the Current Price Sits Inside the Supplied Technical Range in the Available RecordRectangle Pattern - vinanet.vn
Polyrizon Ltd. (PLRZ) Gains 2.14% to $10.98, Holding Support Amid Biotech InterestTPO Profile - vinanet.vn
Polyrizon Ltd. (PLRZ): MMCAP group discloses 9.6% beneficial stake - Stock Titan
DISCLOSED: Insiders Are Now Buying *This Stock* Sootoday.com (Je9ZHM0WVP) - Mshale
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd. (PLRZ) Slips 2.24% as Shares Test Key Support Zone Near $10.76Stock Picks - dars.gov.et
PLRZ.O PE Ratio & Valuation, Is PLRZ.O Overvalued - Intellectia AI
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Earnings Date & Reports & Earnings News - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Cash Flow - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
Polyrizon Ltd (PLRZ) 財務データ
収益
当期純利益
現金流量
EPS
Polyrizon Ltd (PLRZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Carmel Liron | Director |
Mar 31 '26 |
Sale |
12.36 |
942 |
11,643 |
3,127 |
| Adler Oz | Director |
Mar 31 '26 |
Sale |
12.05 |
3,292 |
39,669 |
19,850 |
| Carmel Liron | Director |
Mar 30 '26 |
Sale |
11.00 |
100 |
1,100 |
4,069 |
| Izraeli Tomer | Chief Executive Officer |
Mar 30 '26 |
Sale |
10.90 |
3,900 |
42,510 |
32,012 |
| Turgeman Tidhar | Chief Technology Officer |
Mar 30 '26 |
Sale |
10.90 |
2,917 |
31,795 |
17,518 |
1.48%
0.31%
大文字化:
|
ボリューム (24 時間):